Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRAT | P43155 | 1/20 | 0.61 |
| ▸ | CPT2 | P23786 | 3/20 | 0.55 |
| ▸ | CPT1A | P50416 | 3/20 | 0.55 |
| ▸ | CPT1B | Q92523 | 2/20 | 0.55 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24634587 | 0.84 | CPT2 (0.69) | CRATCPT2CPT1ACPT1BSLC22A16 | |
| SCHEMBL4339313 | 0.76 | CRAT (1.00) | CRATCPT2CPT1ACPT1BSLC22A16 | |
| SCHEMBL5712398 | 0.76 | CRAT (1.00) | CRATCPT2CPT1ACPT1BSLC22A16 | |
| SCHEMBL5712374 | 0.76 | CRAT (1.00) | CRATCPT2CPT1ACPT1BSLC22A16 | |
| SCHEMBL24634589 | 0.73 | CRAT (0.63) | CRATCPT2CPT1ACPT1BSLC22A16 | |
| SCHEMBL27259990 | 0.73 | CPT2 (0.66) | CRATCPT2CPT1ACPT1B | |
| Teglicar SCHEMBL4450575 | 0.71 | CPT2 (1.00) | CRATCPT2CPT1ACPT1B | |
| Teglicar SCHEMBL3685373 | 0.71 | CPT2 (1.00) | CRATCPT2CPT1ACPT1B | |
| Teglicar SCHEMBL3687135 | 0.71 | CPT2 (1.00) | CRATCPT2CPT1ACPT1B | |
| SCHEMBL2912378 | 0.71 | CPT2 (1.00) | CRATCPT2CPT1ACPT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | WAVEBREAK INC (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2022212568-A9 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | 1BASE PHARMACEUTICALS, LLC (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2022212568-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | 1BASE PHARMACEUTICALS, LLC (US) | 2022-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | CPT2, PC, SREBF2 | CRAT 424/4885CPT2 1/4885CPT1A 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.